Stopping Oxytocin in Active Labour: Effects on Birth Outcomes
- Stopping intravenous oxytocin once a pregnant woman enters active labour may make little or no difference to whether a caesarean section is required and appears safe for both...
- Near the time of delivery after 37 weeks of pregnancy, artificial oxytocin is administered through an intravenous drip to initiate uterine contractions or strengthen existing ones.
- The review evaluated nine studies involving 4,814 women treated in hospitals across Denmark, France, India, Iran, Israel, Thailand, Turkey, and the USA.
Stopping intravenous oxytocin once a pregnant woman enters active labour may make little or no difference to whether a caesarean section is required and appears safe for both mother and child, according to an updated review with evidence up to November 17, 2025.
How Oxytocin Governs Labour Progress
Near the time of delivery after 37 weeks of pregnancy, artificial oxytocin is administered through an intravenous drip to initiate uterine contractions or strengthen existing ones. Once active labour is established—defined as the cervix opening at least 4 cm with regular contractions—the body is thought to produce sufficient natural oxytocin to keep labour moving forward. Continuing artificial oxytocin past this threshold can trigger contractions that are too frequent or intense, placing stress on the baby and potentially raising the likelihood of a surgical delivery.
What Nine Hospital Studies Reveal About Stopping Oxytocin
The review evaluated nine studies involving 4,814 women treated in hospitals across Denmark, France, India, Iran, Israel, Thailand, Turkey, and the USA. Researchers sought to determine whether stopping oxytocin at the start of the active phase reduces caesarean rates or introduces other clinical effects. The analysis found that discontinuing the medication may make little or no difference to the total number of caesarean births across eight studies comprising 4,710 women. Furthermore, data from five studies including 3,776 women showed no clear impact on the number of instrumental births.
Contraction Risks and Labour Duration
Stopping oxytocin during active labour may reduce the risk of uterine tachysystole or hyperstimulation, a condition marked by overly frequent or strong contractions, based on data from three studies with 1,371 participants. However, the intervention extended the duration of labour by an average of about 35 minutes across eight studies covering 4,141 women, though this result was very uncertain. Neonatal outcomes showed no clear differences between the two approaches regarding Apgar scores, umbilical cord blood indicators of reduced oxygen supply, or admissions to neonatal units.
Clinical Factors That Guide Decisions
Decisions regarding whether to continue or stop oxytocin infusions require individual clinical discussions between patients and healthcare professionals. Care teams must evaluate the specific clinical situation, including how labour is progressing, the strength and frequency of contractions, and the current well-being of both the mother and the baby. Available monitoring equipment and the personal preferences of the mother also shape these choices, as study participants were aware of their treatment group and different hospitals applied varied definitions for active labour.